Skip to main content
Medical information Clinical review pending

Genetic Testing

MTMR14 Gene Centronuclear Myopathy Type 1 Genetic Test

Genetic test using Next-Generation Sequencing (NGS) to identify mutations in the MTMR14 gene associated with Centronuclear Myopathy Type 1.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
A blood sample (usually 5-10ml) is required. Confirm specific requirements with the laboratory before booking.
Results
Results are typically available within 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
No special preparation is typically required for a blood draw. However, confirm with the laboratory for any specific instructions.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the MTMR14 Gene Centronuclear Myopathy Type 1 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Symptoms suggestive of Centronuclear Myopathy (e.g., muscle weakness, hypotonia, delayed motor milestones).
  • ✓Family history of Centronuclear Myopathy or related neuromuscular disorders.
  • ✓Confirmation of a clinical diagnosis.
  • ✓Genetic counseling and family planning for individuals with a known or suspected MTMR14 mutation.
02

In plain language

What this test helps you understand

This test aids in the diagnosis of Centronuclear Myopathy Type 1 by identifying mutations in the MTMR14 gene. It can help confirm a clinical diagnosis, guide management, and inform genetic counseling for affected individuals and families.
The MTMR14 Gene Centronuclear Myopathy Type 1 NGS Genetic DNA Test is a diagnostic tool used to identify genetic mutations linked to centronuclear myopathy, a rare neurological condition. This test employs Next-Generation Sequencing (NGS) technology to provide detailed insights into the genetic basis of the disorder, supporting accurate diagnosis and management.

This genetic test specifically looks for changes within the MTMR14 gene. Mutations in this gene are known causes of centronuclear myopathy. By analyzing a DNA sample, the test can detect specific genetic alterations that may be responsible for the condition, helping healthcare providers understand the patient's specific situation.

Individuals experiencing symptoms suggestive of centronuclear myopathy, such as muscle weakness, low muscle tone (hypotonia), or developmental delays in motor skills, may be candidates for this test. It is also recommended for individuals with a family history of similar neurological conditions to assess their risk and understand inheritance patterns.

Taking this test can provide several benefits, including a precise diagnosis of centronuclear myopathy, which allows for more effective management of symptoms. Identifying the specific genetic mutation can also inform potential treatment strategies and family planning decisions. The results provide valuable information for neurologists and genetic counselors involved in patient care and help clarify the hereditary aspects of the disorder.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for a blood draw. However, confirm with the laboratory for any specific instructions.
SampleA blood sample (usually 5-10ml) is required. Confirm specific requirements with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) is used to analyze the MTMR14 gene for sequence variations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes the MTMR14 gene specifically. It will not detect mutations in other genes that can cause similar conditions. A negative result does not completely rule out Centronuclear Myopathy if clinical suspicion remains high. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Centronuclear Myopathy Type 1 is a rare genetic neuromuscular disorder characterized by muscle weakness and hypotonia, often present from birth or early childhood.
This test specifically looks for mutations (changes) in the MTMR14 gene, which are known to cause Centronuclear Myopathy Type 1.
Individuals with symptoms like muscle weakness or low muscle tone, especially if present early in life, or those with a family history of similar conditions, should discuss this test with their doctor.
A healthcare professional, often a genetic counselor or neurologist, will interpret the results and discuss their meaning with you.
A negative result means no mutations were found in the MTMR14 gene. However, it doesn't entirely rule out the condition, as other genes can cause similar symptoms. Discuss the results with your doctor.
The current price for this test is 40,000 KSh. Confirm with the laboratory for the most up-to-date pricing.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp